Multidisciplinary Approaches to the Management of Atopic Dermatitis - Episode 6
Real-World Challenges to Providing Evidence-Based Care for Atopic Dermatitis
Published on:
Panelists discuss the 2023 American Academy of Allergy, Asthma & Immunology/ American College of Allergy, Asthma & Immunology (AAAAI/ACAAI) Joint Task Force guidelines, highlighting treatment options with strong recommendations and high certainty of evidence, including biologics/monoclonal antibodies (dupilumab, tralokinumab, lebrikizumab) and Janus kinase (JAK) inhibitors (abrocitinib, baricitinib, upadacitinib) for atopic dermatitis management.
Video content above is prompted by the following:
- 2023 AAAAI/ACAAI Joint Task Force Practice Parameters and Guidelines (Ann Allergy Asthma Immunol 2024;132:274-312).
- Discuss the treatment options with strong recommendations and high certainty of evidence.
- Biologics/monoclonal antibodies: dupilumab, tralokinumab, lebrikizumab
- JAK inhibitors: abrocitinib, baricitinib, upadacitinib
